MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Trastuzumab

CAS No. : 180288-69-1

MCE 國(guó)際站：Trastuzumab

產(chǎn)品活性：Trastuzumab 是一種人源化 IgG1 單克隆抗體,，其以高親和力與 HER2 選擇性結(jié)合,。Trastuzumab 可用于 HER2 陽(yáng)性轉(zhuǎn)移性乳腺癌和 HER2 陽(yáng)性胃癌 的研究,。

研究領(lǐng)域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK  |  Antibody-drug Conjugate/ADC Related

作用靶點(diǎn)：Radionuclide-Drug Conjugates (RDCs)  |  EGFR  |  ADC Antibody

In Vitro: Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1.

In Vivo: Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice.

相關(guān)產(chǎn)品：Antibody Inhibitor Library  |  Osimertinib  |  Cetuximab  |  Gefitinib  |  Erlotinib  |  Trastuzumab deruxtecan  |  Afatinib  |  Lapatinib  |  Genistein  |  AG490  |  Rituximab  |  Trastuzumab emtansine  |  Sacituzumab  |  Tucatinib  |  Neratinib  |  Amivantamab  |  Daratumumab  |  Disitamab vedotin  |  Pertuzumab  |  Dacomitinib  |  AG-1478  |  Panitumumab  |  Patritumab  |  Datopotamab  |  Lazertinib  |  NSC 228155  |  Enfortumab  |  Inebilizumab

熱門產(chǎn)品線：重組蛋白  |  藥物篩選  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介紹:
?   MCE (MedChemExpress) 擁有200 多種全球獨(dú)家化合物庫(kù),，我們致力于為全球科研客戶提供前沿最全的高品質(zhì)小分子活性化合物；
?   50,000 多種高選擇性抑制劑,、激動(dòng)劑涉及各熱門信號(hào)通路及疾病領(lǐng)域,；
?   產(chǎn)品種類涵蓋各種重組蛋白，多肽,，常用試劑盒 ,，更有 PROTAC、ADC 等特色產(chǎn)品,，廣泛應(yīng)用于新藥研發(fā),、生命科學(xué)等科研項(xiàng)目；
?   提供虛擬篩選,，離子通道篩選,，代謝組學(xué)分析檢測(cè)分析，藥物篩選等專業(yè)技術(shù)服務(wù),；
?   設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控,、驗(yàn)證體系；
?   提供 LC/MS,、NMR,、HPLC,、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,，確保產(chǎn)品的高純度,、高品質(zhì)；
?   產(chǎn)品的生物活性多經(jīng)各國(guó)客戶實(shí)驗(yàn)驗(yàn)證,；
?   Nature, Cell, Science 等多種頂級(jí)期刊及制藥專利收錄了MCE客戶的科研成果,；
?   專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展，為您提供全球最新的活性化合物,；
?   與世界各大制藥公司及知名科研機(jī)構(gòu)建立了長(zhǎng)期的合作,。